tiprankstipranks
Trending News
More News >

Telix Pharmaceuticals Announces Director Change

Story Highlights
Telix Pharmaceuticals Announces Director Change

Confident Investing Starts Here:

Telix Pharmaceuticals ( (AU:TLX) ) has provided an update.

Telix Pharmaceuticals Limited announced the cessation of Harry Kevin McCann as a director effective May 21, 2025. McCann held indirect interests in the company through Monjoy Pty Limited and Cottesloe Pty Limited, with a total of 1,120,000 fully paid ordinary shares. This change in the board may impact the company’s governance structure and could have implications for its strategic direction.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited operates in the biotechnology sector, focusing on developing diagnostic and therapeutic products for cancer and rare diseases. The company is known for its innovative approach in the field of molecularly targeted radiation therapy, aiming to improve patient outcomes in oncology.

Average Trading Volume: 1,953,939

Technical Sentiment Signal: Buy

Current Market Cap: A$8.7B

Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1